A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma

BACKGROUND: Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy. Despite the virus-associated and immunogenic nature of this disease, novel immunotherapy options that exploit this advantage are curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeku, Oladapo, Russo, Andrea L., Lee, Hang, Spriggs, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491059/
https://www.ncbi.nlm.nih.gov/pubmed/32928237
http://dx.doi.org/10.1186/s12967-020-02523-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491059/
https://www.ncbi.nlm.nih.gov/pubmed/32928237
http://dx.doi.org/10.1186/s12967-020-02523-5

Ejemplares similares